Beta-blocker status according to cardiovascular risk factors for mortality
| No therapy | On therapy | P value | |
| Age (years) | 79±9 | 77±9 | <0.001* |
| NT-proBNP (pg/mL) | 849±628 | 1053±960 | <0.001* |
| Gender (male) | 391 (51%) | 373 (49%) | 0.43† |
| Hypertension | 546 (49%) | 564 (51%) | <0.001† |
| Diabetes | 130 (42%) | 177 (58%) | <0.001† |
| Ischaemic heart disease | 145 (36%) | 261 (64%) | <0.001† |
| Valvular heart disease | 71 (56%) | 56 (44%) | 0.39 |
| Previous MI | 42 (34%) | 83 (66%) | <0.001† |
| Chronic kidney disease | 555 (53%) | 482 (47%) | 0.20 |
| Atrial fibrillation | 230 (37%) | 384 (63%) | <0.001† |
*ANOVA test with Tukey-Kramer post-hoc analysis.
†Χ2 test.
ANOVA, analysis of variance; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain-type natriuretic peptide.